As a pioneer and the undisputed global leader in antibody discovery and development, Creative Biolabs is professional in the in vitro diagnostic (IVD) antibody development and offers the best quality services of IVD antibody discovery against various markers for lung cancer with our diverse technologies.
General Introduction of CYFRA21-1
The cytoskeleton is a complex filamentous cytoplasmic structure that may influence dynamic cell morphology in the tissue environment. It is composed of different types of filaments with different sizes such as actin, intermediate filaments, myosine and microtubules. As the major component of intermediate filaments, cellular cytokeratins consist of heterodimers, each containing one type I (acidic) and one type II (basic) cytokeratin filament. Cytokeratin 19 (Ck19; type I -40 kDa) is only expressed in simple epithelia, such as the unstratified or pseudo-stratified epithelium of the bronchial tree. Immunohistochemical studies revealed that Ck 19 enhanced expression in malignant lung tissues, compared with expression in normal lung epithelium. The cytokeratin pattern is well preserved while the transformation from normal to malignant tissue, which may be helpful in classifying lung tumours. CYFRA 21-1 is a new tumour marker measuring Ck 19 fragments in serum with higher sensitivity and specificity, compared to other tumour markers used for NSCLC, such as CEA, TPA and SCC.
Fig.1 A 3-step diagnostic workflow based on tumor markers for patients in ESCC.1
The Important Role of Circulating CYFRA21-1 In Metastasis Diagnosis
According to reports, it suggested that CYFRA21-1 appears to be the most sensitive and specific marker for NSCLC diagnosis and was found to be of prognostic values in patients with recurrent NSCLC receiving gefitinib therapy. High levels of CYFRA21-1 correlated with survival status in ADC and SCLC but not in SCC patients. It also could be used as an independent predictor of poor prognosis in ADC and SCLC patients. Currently, NSE is the most widely used marker for diagnosis and prognosis of SCLC patients because positive levels of NSE significantly correlated with survival in SCLC. However, NSE did not qualify as an independent predictor for poor prognosis. Relationship between elevated levels of CYFRA21-1 biomarkers and metastasis, survival status and prognosis in lung cancer patients were investigated and indicated the important role of CYFRA21-1 in predicting the occurrence of metastasis as well as poor prognosis in lung cancer patients.
The clinical diagnostic methods of lung cancer include computed tomography (CT), chest x-ray and needle biopsy of the lung. But beyond that, a laboratory test also plays an auxiliary role in lung cancer diagnostic test. CYFRA21-1 is more important in metastasis occurrence and in predicting poor prognosis in lung cancer patients than CEA, NSE and positive numbers of biomarkers. The CYFRA21-1 test can not only contribute to the diagnostic application but also help the doctor plan and monitor treatment of patients with lung cancer.
IVD antibodies are important tools to provide information regarding the diagnosis, prognosis, and management of lung cancer. Since CYFRA21-1 is a potential marker of lung cancer, CYFRA21-1-specific antibodies can be developed and engineered to aid in lung cancer diagnosis. At Creative Biolabs, we’re skilled at the monoclonal, polyclonal, and recombinant antibody development services for diagnostic uses. With our versatile IVD platform, Creative Biolabs is proud to develop novel CYFRA21-1-specific antibody from scratch to commercial IVD kit (we can also start with provided antibody candidates).
If you are interested in discovering novel CYFRA21-1-specific antibody, please do not hesitate to contact us for more details.
Reference
For Research Use Only.
